Skip to Content

Zolinza (vorinostat) Disease Interactions

There are 5 disease interactions with Zolinza (vorinostat):

Major

Vorinostat (applies to Zolinza) thromboembolism

Major Potential Hazard, Moderate plausibility. Applicable conditions: Thrombotic/Thromboembolic Disorder

The use of vorinostat may cause pulmonary embolism and deep vein thrombosis. It is recommended to monitor for signs and symptoms of these events, particularly in patients with a prior history of thromboembolic events.

Moderate

Vorinostat (applies to Zolinza) diabetes

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Diabetes Mellitus

The use of vorinostat may cause hyperglycemia. It is recommended to monitor serum glucose every 2 weeks during the first 2 months of therapy and monthly thereafter. Care should be exercised when using this agent in diabetic patients.

Moderate

Vorinostat (applies to Zolinza) GI disturbances

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Vomiting, Diarrhea, Electrolyte Abnormalities, Hypokalemia, Magnesium Imbalance

The use of vorinostat may cause gastrointestinal disturbances. It is recommended to adequately control any preexisting nausea, vomiting, and diarrhea prior to beginning treatment with vorinostat. Fluid and electrolytes should be replaced to prevent dehydration and the use of antiemetic and antidiarrheal medications may be appropriate. Correct hypokalemia and hypomagnesemia prior to administration of vorinostat. Monitor potassium and magnesium more frequently in symptomatic patients.

Moderate

Vorinostat (applies to Zolinza) liver impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Compared to patients with normal liver function, AUC increases of 50 to 66% were observed in patients with hepatic impairment. It is recommended to reduce the starting dose of vorinostat to 300 mg orally once daily with food in patients with mild to moderate hepatic impairment (bilirubin 1 to 3 × ULN or AST greater than ULN). There is insufficient evidence to recommend a starting dose for patients with severe hepatic impairment (bilirubin greater than 3 × ULN). Precautions should be instituted when using this agent in patients with liver dysfunction.

Moderate

Vorinostat (applies to Zolinza) myelosuppression

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Bone Marrow Depression/Low Blood Counts

The use of vorinostat can cause dose-related thrombocytopenia and anemia. It is recommended to monitor blood counts every 2 weeks during the first 2 months of therapy and monthly thereafter. Adjust dosage or discontinue treatment as clinically appropriate. Care should be exercised when using this agent in patients with bone marrow suppression.

Zolinza (vorinostat) drug interactions

There are 54 drug interactions with Zolinza (vorinostat)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.